vTv Therapeutics Inc. (NASDAQ:VTVT) fell 9.2% during trading on Tuesday . The stock traded as low as $2.11 and last traded at $2.37. 3,249,538 shares changed hands during mid-day trading, a decline of 32% from the average session volume of 4,750,907 shares. The stock had previously closed at $2.61.
Separately, Zacks Investment Research downgraded vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 9th.
The company has a 50-day simple moving average of $2.32 and a 200 day simple moving average of $2.06. The company has a market capitalization of $175.10 million, a P/E ratio of -5.30 and a beta of -2.00.
Several large investors have recently made changes to their positions in the company. XTX Markets LLC acquired a new stake in shares of vTv Therapeutics during the 4th quarter worth approximately $27,000. JPMorgan Chase & Co. grew its holdings in shares of vTv Therapeutics by 227.6% during the 4th quarter. JPMorgan Chase & Co. now owns 26,388 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 18,334 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in shares of vTv Therapeutics during the 4th quarter worth approximately $65,000. GSA Capital Partners LLP acquired a new stake in shares of vTv Therapeutics during the 3rd quarter worth approximately $68,000. Finally, BlackRock Inc. grew its holdings in shares of vTv Therapeutics by 13.4% during the 3rd quarter. BlackRock Inc. now owns 373,319 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 44,191 shares in the last quarter. 5.07% of the stock is currently owned by institutional investors.
vTv Therapeutics Company Profile (NASDAQ:VTVT)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.